U.S. markets closed
  • S&P Futures

    4,069.75
    -5.75 (-0.14%)
     
  • Dow Futures

    34,440.00
    -19.00 (-0.06%)
     
  • Nasdaq Futures

    11,992.00
    -18.25 (-0.15%)
     
  • Russell 2000 Futures

    1,893.40
    -1.00 (-0.05%)
     
  • Crude Oil

    81.37
    +1.39 (+1.74%)
     
  • Gold

    1,820.70
    +11.10 (+0.61%)
     
  • Silver

    23.58
    +0.33 (+1.44%)
     
  • EUR/USD

    1.0562
    +0.0031 (+0.30%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • Vix

    19.06
    -0.78 (-3.93%)
     
  • GBP/USD

    1.2316
    +0.0020 (+0.16%)
     
  • USD/JPY

    134.4340
    +0.1630 (+0.12%)
     
  • BTC-USD

    17,261.20
    +290.33 (+1.71%)
     
  • CMC Crypto 200

    408.47
    +7.04 (+1.75%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,800.41
    +22.51 (+0.08%)
     

Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

NEW HAVEN, Conn., August 31, 2022--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA.

A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005665/en/

Contacts

Investor Contacts
Steven Tuch
Head of Corporate Development
415-218-0697
stuch@rallybio.com

Ami Bavishi
Head of Investor Relations and Communications
609-477-4536
abavishi@rallybio.com

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Tara DiMilia
908-369-7168
Tara.dimilia@tmstrat.com